Speakers
Jennifer Andres, MSN, RN, FNP-C, OCN, BMTCN
Hematology Nurse Practitioner
Mayo Clinic
Phoenix, Arizona, USA
Jennifer Andres, MSN, RN, FNP-C received her Bachelor of Science in Nursing from Creighton University in Omaha, Nebraska in 2006. Following graduation, she joined Mayo Clinic in Arizona as a nurse on the Hematology/Oncology/Bone Marrow Transplant unit for eight years. She served in multiple roles, including that of staff nurse, resource nurse, preceptor, and team lead. During this time, she obtained her Oncology Certified Nurse (OCN) and Blood and Marrow Transplant Certified Nurse (BMTCM) certifications. In 2014, Jennifer transitioned to a Nursing Informatics Specialist role where she provided support in ambulatory care areas including Hematology, Oncology and Clinical Research. In 2015, she began working on her Master of Science in Nursing and transitioned back to her previous patient care role. She earned her MSN with her Family Nurse Practitioner certification in 2018 from Grand Canyon University in Phoenix.
Jeanne M. Palmer, MD
Vice Chair and Section Chief for Hematology
Program Director for the Blood and Marrow Transplant Program
Mayo Clinic Medical School
University of Arizona
Phoenix, AZ, USA
Dr. Jeanne Palmer is an Associate Professor of Medicine at Mayo Clinic in Phoenix AZ. She also serves as the Section Head of Hematology at Mayo Clinic Arizona, and is the Director of the Blood and Marrow transplant program. She received her MD from New York Medical College, completed residency in Internal Medicine at Columbia Presbyterian and fellowship in hematology/oncology at Duke University Medical Center.
Dr. Palmer is involved in the care of patients with myeloproliferative diseases, offering clinical trials for patients with myeloproliferative diseases, as well as bone marrow transplants for patients with myelofibrosis. She has been involved in numerous clinical trials and research efforts.
She believes in individualized care of patients with myeloproliferative disorders, addressing the medical issues associated with these diseases as well as the symptom burden.
Accreditation and Disclosure Information
Target Audience
This educational activity is designed for academic and community nurses and nurse practitioners who treat and manage patients with myelofibrosis.
Educational Objectives
After completing this CE activity, the participant should be better able to:
- Correctly evaluate the alignment of JAK inhibitors and emerging treatment options with evidence-based clinical guidelines for patients diagnosed with MF
- Appropriately assess patient symptoms and potential adverse events related to JAK inhibitors and emerging treatment options to effectively address patient QOL
- Consistently implement shared decision-making strategies to create a personalized care plan that alleviates QOL burdens associated with MF
Agenda
Part 1: Making an Appropriate Treatment Selection for Patients with MF
Understanding How Patient Risk and Drug Mechanism of Action Leads to Effective Treatment and Management Decisions
- Discuss the professional clinical guidelines and the role JAK inhibitors as well as other emerging treatment options for patients with primary or secondary MF.
- Delve into the patient characteristics and risk factors that impact treatment decisions, specifically if a patient has intermediate- or high-risk MF.
- Review of disease pathophysiology and understanding of treatment selection based on drug mechanism of action (i.e., JAK inhibitors, erythroid maturation agents, BCL-2 inhibitors, and BET inhibitors).
Recognizing the Gaps in MF Care that Influence Patient QOL
- Examine the gaps in care for patients with MF including the need to appropriately assess symptom severity, suboptimal relief from symptoms, need for dosing modification, and accurately recognizing treatment failure.
- Understand the efficacy and safety data of emerging treatment options for MF.
Part 2: Accounting for Patient QOL Based on MF- and Treatment-Related Factors
Increasing Familiarity with Disease- and Treatment-Related Adverse Events
- Evaluate current unmet needs in patient care for symptom control and impact on patient QOL.
- Account for differences and how to manage both disease-related symptoms and treatment related adverse events and provide necessary education for patients on how to best manage both as well address patient concerns.
Establishing Trust with Patients to Improve Outcomes and QOL
- Provide education that enhances patient trust in order to provide optimal MF care and addresses unmet patient needs.
- Review of effective communication with patients to adequately assess QOL burden.
- Provide education that enhances patient trust in order to provide optimal MF care and addresses unmet patient needs.
- Review of effective communication with patients to adequately assess QOL burden.
Part 3: Effective Strategies for Shared Decision-Making in MF Care
Finding value in shared decision-making and the unique role of multidisciplinary teams
- Incorporate clinical and patient goals into conversations regarding treatment decisions with patients.
- Integrate patient engagement through multidisciplinary teams in order to manage symptoms, improve QOL and advance overall survival benefit.
- Develop workflows to help advocate for patients as well as enhance their overall QOL.
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
ILNA Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
1.0 points: Care Continuum (OCN, CBCN, CPHON, AOCNP)
1.0 points: Oncologic Emergencies (OCN, CPHON, AOCNP); Oncology Nursing Practice (OCN); Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN); Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP); Treatment (OCN, CBCN, AOCNP, CPHON)
The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.
Support Statement
This activity is supported by an educational grant from CTI Biopharma Corp., a Sobi Company.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Jennifer Andres, MSN, RN, FNP-C, OCN, BMTCN
Hematology Nurse Practitioner
Mayo Clinic
Phoenix, AZ, USA
Ms. Andres has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Jeanne Palmer, MD
Vice Chair and Section Chief for Hematology
Program Director for the Blood and Marrow Transplant Program
Mayo Clinic Medical School
University of Arizona
Phoenix, AZ, USA
Dr. Palmer has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: MorphoSys (advisory board, money went to Mayo)
Speakers’ Bureau: Merck (speaker at EHA in a session funded by Merck)
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute, Inc | All Rights Reserved